Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Business Exposures
Activism
Animal Testing
Artificial Intelligence
Boeing 737
Brexit
Cannabis
Censorship
Climate
Coal
COVID-19
Criminal
Death
Debt Markets
Derivatives
Diversity
Economy
Electric Vehicles
Electricity Generation
Ethanol
Financial
Firearms
Fossil Fuels
Glyphosate
Harassement
Immigration
Information Security
Intellectual Property
Interest Rates
Labor
Layoff
Lead
Legal
Palm Oil
Pension
Political
Product Safety
Regulatory
Religion
Securities Market
Supply Chain
Tariff
Textiles
US Equities
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
United Health Products Submits Full FDA PMA Application
March 21, 2024
Via
NewMediaWire
Exposures
Product Safety
Tickers
UEEC
United Health Products Submits Full FDA PMA Application
March 21, 2024
Via
TheNewswire.com
Exposures
Product Safety
Tickers
UEEC
Freezies Treats to Expand Operations, Bringing Joy Beyond Borders
March 20, 2024
Via
Get News
Topics
Product Recall
Exposures
COVID-19
Legal
Product Safety
BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) on Promising Path to Meet Medical Needs of ASD Patients
March 20, 2024
Via
Investor Brand Network
Exposures
Product Safety
Tickers
PXMD
CCHR Raises Concerns About Native Americans Defrauded in Mental Health System
March 18, 2024
Via
PRLog
Topics
Fraud
Exposures
Legal
Product Safety
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Exercises Option for Exclusive License Agreement for SPC-15
March 20, 2024
Via
Investor Brand Network
Exposures
Product Safety
Tickers
SILO
Geron Stock Doubles After Imetelstat Receives FDA Panel Approval
March 20, 2024
Via
MarketBeat
Exposures
Product Safety
Tickers
BMY
CRSP
GERN
MRK
XORTX: A Year of Milestones and Strategic Advancements as it Readies for a Registration Clinical Trial
March 19, 2024
Via
Get News
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Tickers
XRTX
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages InMode Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - INMD
March 19, 2024
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Product Safety
Tickers
INMD
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages InMode Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - INMD
March 19, 2024
Via
TheNewswire.com
Topics
Lawsuit
Exposures
Financial
Legal
Product Safety
Tickers
INMD
Endocrine Disease-Focused Crinetics Pharmaceuticals Stock Soars On Tuesday - Here's Why
March 19, 2024
Via
Benzinga
Exposures
Product Safety
Tickers
CRNX
Why Blood Components-Focused Cerus Stock Is Rising Tuesday
March 19, 2024
Via
Benzinga
Exposures
Product Safety
Tickers
CERS
Ferrari Faces Lawsuit In US Over Brake Defect: Report
March 19, 2024
Via
Benzinga
Topics
Lawsuit
Product Recall
Exposures
Financial
Legal
Product Safety
Tickers
RACE
Medications for Type 2 diabetes, weight loss & kidney health not always provided as needed
March 19, 2024
Via
NewMediaWire
Exposures
Product Safety
TinyGemsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces $6.5M Registered Direct Offering
March 19, 2024
Via
Investor Brand Network
Exposures
Product Safety
Tickers
GNPX
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces $6.5M Registered Direct Offering
March 19, 2024
Via
Investor Brand Network
Exposures
Product Safety
Tickers
GNPX
Bayer's Third Menopausal Relief Drug Trial Meets Primary Goal, German Conglomerate Seeks FDA Approval For Elinzanetant
March 19, 2024
Via
Benzinga
Exposures
Product Safety
Tickers
ACER
BAYRY
BAYZF
XORTX: A Year of Milestones and Strategic Advancements as it Readies for a Registration Clinical Trial
March 19, 2024
Via
News Direct
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Tickers
XRTX
XORTX: A Year of Milestones and Strategic Advancements as it Readies for a Registration Clinical Trial
March 19, 2024
Via
TheNewswire.com
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Tickers
XRTX
Did Novo Nordisk Just Get a Jump on Eli Lilly?
March 19, 2024
Via
The Motley Fool
Exposures
Product Safety
Tickers
CTLT
LLY
NVO
Is Madrigal Pharmaceuticals Stock a Better Buy Than Eli Lilly and Novo Nordisk After Its Huge FDA Win?
March 19, 2024
Via
The Motley Fool
Exposures
Product Safety
Tickers
LLY
MDGL
NVO
AGC Biologics to Manufacture First-ever FDA Approved Gene Therapy for Early-onset Metachromatic Leukodystrophy, Orchard Therapeutics’ Lenmeldy™ (atidarsagene autotemcel)
March 19, 2024
Via
News Direct
Exposures
Product Safety
Bestqool Unveils Comprehensive Guide to Optimize Red Light Therapy Dosage for Enhanced Health Benefits
March 18, 2024
Via
Get News
Exposures
Product Safety
Inconsistent Insurance Coverage For Weight Loss Drugs - Novo Nordisk's GLP-1s Face Hurdles Despite Health Benefits
March 18, 2024
Via
Benzinga
Exposures
Product Safety
Tickers
CI
NVO
C Distinctive Eyewear Adds Lumenis OptiLight IPL for Dry Eye Treatment
March 18, 2024
Via
Press Advantage
Exposures
Product Safety
FDA Adcomm Favors Expanded Use Of Johnson & Johnson, Bristol Myers' CAR-T Therapies For Type Of Blood Cancer
March 18, 2024
Via
Benzinga
Exposures
Product Safety
Tickers
BMY
JNJ
LEGN
TSVT
Lexaria Bioscience Corp. (NASDAQ: LEXX) Marks Huge 2024 Milestone with FDA Clearance for its Planned U.S. Phase 1b Hypertension Clinical Trial
March 18, 2024
Via
Investor Brand Network
Exposures
Product Safety
Tickers
LEXX
Powerful Medical's AI Breakthrough Marks a New Dawn in Heart Attack Diagnostics with EIC Support Doubles Sensitivity in Identifying Acute Coronary Occlusion on 12-Lead ECG
March 18, 2024
Via
Newsfile
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Product Safety
Faron Pharmaceuticals reports promising phase 1 results from BEXMAB study
March 18, 2024
Via
News Direct
Exposures
Product Safety
Faron Pharmaceuticals reports promising phase 1 results from BEXMAB study
March 18, 2024
Via
TheNewswire.com
Exposures
Product Safety
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.